Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Observer-Blind, Controlled Study to Assess the Safety, Immunogenicity and Efficacy of the SARS-CoV-2 Self- Amplifying RNA Vaccine ARCT-154 in Adults

NCT05012943 is registered in ClinicalTrials.gov with Vinbiocare Biotechnology Joint Stock Company as lead sponsor.

NCT NCT05012943
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05012943 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Observer-Blind, Controlled Study to Assess the Safety, Immunogenicity and Efficacy of the SARS-CoV-2 Self- Amplifying RNA Vaccine ARCT-154 in Adults
Lead sponsor
Vinbiocare Biotechnology Joint Stock Company
Phase
Phase 2/3
Overall status
Completed
Start date
August 15, 2021
Completion date
January 18, 2023
Enrollment
19,474 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 vaccines